BR112015006363A2 - combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r - Google Patents

combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r

Info

Publication number
BR112015006363A2
BR112015006363A2 BR112015006363A BR112015006363A BR112015006363A2 BR 112015006363 A2 BR112015006363 A2 BR 112015006363A2 BR 112015006363 A BR112015006363 A BR 112015006363A BR 112015006363 A BR112015006363 A BR 112015006363A BR 112015006363 A2 BR112015006363 A2 BR 112015006363A2
Authority
BR
Brazil
Prior art keywords
vegf
agents
pharmaceutical combinations
binders
angiopoietin
Prior art date
Application number
BR112015006363A
Other languages
English (en)
Inventor
Gschwind Andreas
Baum Anke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015006363(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112015006363A2 publication Critical patent/BR112015006363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo "combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r" a presente invenção se refere a combinações farmacêuticas que compreendem ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r para uso no tratamento de doenças como câncer e doenças oculares. são ainda descritos ligantes anti-ang2/anti-dll4 duplos para uso no tratamento de câncer em combinação com agentes anti-vegf-r, e composições farmacêuticas compreendendo as combinações farmacêuticas da invenção.
BR112015006363A 2012-09-28 2013-09-26 combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r BR112015006363A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12186695 2012-09-28
PCT/EP2013/070143 WO2014049099A1 (en) 2012-09-28 2013-09-26 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents

Publications (1)

Publication Number Publication Date
BR112015006363A2 true BR112015006363A2 (pt) 2017-08-08

Family

ID=46963602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006363A BR112015006363A2 (pt) 2012-09-28 2013-09-26 combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r

Country Status (17)

Country Link
US (1) US20140093498A1 (pt)
EP (1) EP2900261A1 (pt)
JP (1) JP2015532272A (pt)
KR (1) KR20150060687A (pt)
CN (1) CN104661678A (pt)
AR (1) AR092736A1 (pt)
AU (1) AU2013322640A1 (pt)
BR (1) BR112015006363A2 (pt)
CA (1) CA2883807A1 (pt)
CL (1) CL2015000761A1 (pt)
EA (1) EA201500370A1 (pt)
IL (1) IL237645A0 (pt)
MX (1) MX2015003895A (pt)
PH (1) PH12015500663A1 (pt)
TW (1) TW201427688A (pt)
UY (1) UY35054A (pt)
WO (1) WO2014049099A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
CA2963606A1 (en) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
BR112017009817A2 (pt) 2014-11-10 2018-02-14 Hoffmann La Roche anticorpos anti-il-1beta e métodos de utilização
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
PT3253208T (pt) 2015-02-02 2021-06-17 The Spanish National Cancer Res Centre Terapêuticas de combinação para utilização no tratamento do cancro da mama
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
KR20090016762A (ko) * 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
WO2008060705A2 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20110118185A9 (en) 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EA029996B1 (ru) 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
EP2344536A1 (en) * 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011014726A1 (en) * 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2

Also Published As

Publication number Publication date
KR20150060687A (ko) 2015-06-03
PH12015500663A1 (en) 2015-05-18
WO2014049099A1 (en) 2014-04-03
EP2900261A1 (en) 2015-08-05
MX2015003895A (es) 2015-07-17
AU2013322640A1 (en) 2015-03-12
AR092736A1 (es) 2015-04-29
UY35054A (es) 2014-04-30
CA2883807A1 (en) 2014-04-03
CN104661678A (zh) 2015-05-27
CL2015000761A1 (es) 2015-08-07
US20140093498A1 (en) 2014-04-03
TW201427688A (zh) 2014-07-16
IL237645A0 (en) 2015-04-30
EA201500370A1 (ru) 2015-08-31
JP2015532272A (ja) 2015-11-09

Similar Documents

Publication Publication Date Title
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
GB201209613D0 (en) New compounds
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112014026703A2 (pt) inibidores de dna-pk
PH12015500664A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
MX369803B (es) Derivados de acilaminopirimidina para el tratamiento de infecciones viricas y otras enfermedades.
BR112015003751A2 (pt) conjugados da anticorpo-droga (adc) que se ligam a proteínas 158p1d7
BR112015004875A2 (pt) formulações de anticorpo e seus usos
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112014027047A2 (pt) nova formulação
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]